Halozyme Therapeutics Stock Price, News & Analysis (NASDAQ:HALO)

$18.48 -0.06 (-0.32 %)
(As of 02/21/2018 02:25 PM ET)
Previous Close$18.48
Today's Range$18.42 - $18.95
52-Week Range$11.41 - $21.13
Volume1.04 million shs
Average Volume1.20 million shs
Market Capitalization$2.64 billion
P/E Ratio-28.90
Dividend YieldN/A
Beta1.99

About Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics logoHalozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex recombinant. The Company's development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).

Receive HALO News and Ratings via Email

Sign-up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:HALO
CUSIP40637H10
Phone858-794-8889

Debt

Debt-to-Equity Ratio2.01%
Current Ratio3.46%
Quick Ratio3.37%

Price-To-Earnings

Trailing P/E Ratio-28.8966338730313
Forward P/E Ratio71.08
P/E GrowthN/A

Sales & Book Value

Annual Sales$146.69 million
Price / Sales17.93
Cash FlowN/A
Price / CashN/A
Book Value($0.25) per share
Price / Book-73.92

Profitability

Trailing EPS($0.68)
Net Income$-103,020,000.00
Net Margins-53.17%
Return on Equity-892.57%
Return on Assets-29.67%

Miscellaneous

Employees259
Outstanding Shares142,360,000

Halozyme Therapeutics (NASDAQ:HALO) Frequently Asked Questions

What is Halozyme Therapeutics' stock symbol?

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

How were Halozyme Therapeutics' earnings last quarter?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) released its earnings results on Tuesday, February, 20th. The biopharmaceutical company reported $0.85 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.58 by $0.27. The biopharmaceutical company earned $189.60 million during the quarter, compared to the consensus estimate of $173.11 million. Halozyme Therapeutics had a negative net margin of 53.17% and a negative return on equity of 892.57%. The company's revenue was up 386.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.21) EPS. View Halozyme Therapeutics' Earnings History.

Where is Halozyme Therapeutics' stock going? Where will Halozyme Therapeutics' stock price be in 2018?

8 analysts have issued 12 month target prices for Halozyme Therapeutics' stock. Their forecasts range from $7.00 to $29.00. On average, they anticipate Halozyme Therapeutics' stock price to reach $19.38 in the next twelve months. View Analyst Ratings for Halozyme Therapeutics.

Who are some of Halozyme Therapeutics' key competitors?

Who are Halozyme Therapeutics' key executives?

Halozyme Therapeutics' management team includes the folowing people:

  • Connie L. Matsui, Chairman of the Board (Age 63)
  • Helen I Torley, President, Chief Executive Officer, Director (Age 54)
  • Laurie D. Stelzer, Chief Financial Officer, Senior Vice President (Age 49)
  • Harry J. Leonhardt Esq., Senior Vice President, Chief Compliance Officer, General Counsel (Age 60)
  • Athena M. Countouriotis M.D., Senior Vice President, Chief Medical Officer (Age 45)
  • Jean-Pierre Bizzari M.D., Independent Director (Age 62)
  • James M. Daly, Independent Director (Age 55)
  • Jeffrey William Henderson, Independent Director (Age 52)
  • Kenneth J. Kelley, Independent Director (Age 57)
  • Randal J. Kirk, Independent Director (Age 63)

Who owns Halozyme Therapeutics stock?

Halozyme Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.50%), Iridian Asset Management LLC CT (6.16%), Snyder Capital Management L P (1.66%), Bank of New York Mellon Corp (1.30%), Millennium Management LLC (1.04%) and Geode Capital Management LLC (0.88%). View Institutional Ownership Trends for Halozyme Therapeutics.

Who sold Halozyme Therapeutics stock? Who is selling Halozyme Therapeutics stock?

Halozyme Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Senzar Asset Management LLC, Iridian Asset Management LLC CT, Bank of New York Mellon Corp, The Manufacturers Life Insurance Company , Snyder Capital Management L P, BlackRock Inc., Granite Investment Partners LLC and Kennedy Capital Management Inc.. View Insider Buying and Selling for Halozyme Therapeutics.

Who bought Halozyme Therapeutics stock? Who is buying Halozyme Therapeutics stock?

Halozyme Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Millennium Management LLC, Two Sigma Advisers LP, Bogle Investment Management L P DE, Goldman Sachs Group Inc., American Century Companies Inc., Two Sigma Investments LP and Artal Group S.A.. View Insider Buying and Selling for Halozyme Therapeutics.

How do I buy Halozyme Therapeutics stock?

Shares of Halozyme Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Halozyme Therapeutics' stock price today?

One share of Halozyme Therapeutics stock can currently be purchased for approximately $18.48.

How big of a company is Halozyme Therapeutics?

Halozyme Therapeutics has a market capitalization of $2.64 billion and generates $146.69 million in revenue each year. The biopharmaceutical company earns $-103,020,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. Halozyme Therapeutics employs 259 workers across the globe.

How can I contact Halozyme Therapeutics?

Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected]


MarketBeat Community Rating for Halozyme Therapeutics (HALO)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  260 (Vote Outperform)
Underperform Votes:  191 (Vote Underperform)
Total Votes:  451
MarketBeat's community ratings are surveys of what our community members think about Halozyme Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Halozyme Therapeutics (NASDAQ:HALO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.382.332.292.50
Ratings Breakdown: 1 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
3 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $19.38$18.67$18.00$14.86
Price Target Upside: 4.84% upside2.78% downside6.25% downside17.45% upside

Halozyme Therapeutics (NASDAQ:HALO) Consensus Price Target History

Price Target History for Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics (NASDAQ:HALO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/21/2018JPMorgan Chase & Co.Boost Price TargetOverweight -> Overweight$19.00 -> $22.00HighView Rating Details
1/24/2018Deutsche BankSet Price TargetBuy$21.00LowView Rating Details
1/24/2018Goldman Sachs GroupInitiated CoverageNeutral -> Neutral$20.00HighView Rating Details
11/22/2017BarclaysDowngradeOverweight -> Hold$16.00 -> $19.00N/AView Rating Details
11/8/2017Canaccord GenuityBoost Price TargetBuy$17.00 -> $19.00N/AView Rating Details
11/8/2017BMO Capital MarketsBoost Price TargetMarket Perform$15.00 -> $18.00N/AView Rating Details
10/16/2017Piper Jaffray CompaniesBoost Price TargetOverweight -> Overweight$26.00 -> $29.00N/AView Rating Details
8/10/2017Jefferies GroupReiterated RatingUnderperform$6.75 -> $7.00HighView Rating Details
1/6/2017CitigroupDowngradeBuy -> NeutralN/AView Rating Details
9/8/2016Wells Fargo & CoReiterated RatingBuyN/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$22.00 -> $20.00N/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Halozyme Therapeutics (NASDAQ:HALO) Earnings History and Estimates Chart

Earnings by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics (NASDAQ HALO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/20/2018Q4 2017$0.58$0.85$173.11 million$189.60 millionViewListenView Earnings Details
11/7/2017Q3 2017$0.06$0.02$58.95 million$63.73 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.25)($0.23)$31.76 million$33.80 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.25)($0.26)$30.79 million$29.60 millionViewListenView Earnings Details
2/28/2017Q416($0.30)($0.21)$37.94 million$39.00 millionViewListenView Earnings Details
11/7/2016Q316($0.27)($0.23)$34.43 million$31.90 millionViewListenView Earnings Details
8/9/2016Q216($0.27)($0.21)$29.94 million$33.30 millionViewN/AView Earnings Details
5/9/2016Q116($0.20)($0.16)$29.65 million$42.50 millionViewN/AView Earnings Details
2/29/2016Q415($0.08)$0.03$37.06 million$52.20 millionViewListenView Earnings Details
11/9/2015Q315($0.16)($0.19)$24.01 million$20.80 millionViewN/AView Earnings Details
8/10/2015Q215($0.09)$0.02$24.84 million$43.40 millionViewListenView Earnings Details
5/11/2015Q115($0.13)($0.12)$19.40 million$18.70 millionViewListenView Earnings Details
3/2/2015Q414($0.07)($0.04)$25.60 million$30.38 millionViewN/AView Earnings Details
11/10/2014Q314($0.14)($0.16)$16.50 million$14.60 millionViewN/AView Earnings Details
8/11/2014Q214($0.18)($0.13)$13.71 million$18.40 millionViewN/AView Earnings Details
5/12/2014Q114($0.14)($0.22)$13.37 million$12.00 millionViewN/AView Earnings Details
2/27/2014Q413($0.17)($0.19)$21.80 million$12.50 millionViewN/AView Earnings Details
11/8/2013Q313($0.15)($0.17)$14.62 million$16.00 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.13)($0.13)$11.29 million$14.50 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.15)($0.17)$7.05 million$11.83 millionViewN/AView Earnings Details
2/25/2013Q4 2012($0.16)($0.04)$7.32 million$21.80 millionViewN/AView Earnings Details
11/8/2012Q312($0.13)($0.18)$6.09 million$5.33 millionViewN/AView Earnings Details
8/6/2012($0.15)($0.13)ViewN/AView Earnings Details
5/7/2012($0.11)$0.14ViewN/AView Earnings Details
3/9/2012($0.16)($0.18)ViewN/AView Earnings Details
11/7/2011($0.03)$0.05ViewN/AView Earnings Details
8/5/2011Q2 2011($0.13)$0.03ViewN/AView Earnings Details
5/6/2011Q1 2011($0.13)($0.10)ViewN/AView Earnings Details
3/11/2011Q4 2010($0.12)($0.17)ViewN/AView Earnings Details
11/5/2010Q3 2010($0.13)($0.13)ViewN/AView Earnings Details
8/6/2010Q2 2010($0.14)($0.13)ViewN/AView Earnings Details
5/7/2010Q1 2010($0.16)($0.13)ViewN/AView Earnings Details
3/12/2010Q4 2009($0.16)($0.14)ViewN/AView Earnings Details
11/6/2009Q3 2009($0.18)($0.16)ViewN/AView Earnings Details
8/7/2009Q2 2009($0.16)($0.21)ViewN/AView Earnings Details
5/8/2009Q1 2009($0.15)($0.18)ViewN/AView Earnings Details
3/13/2009Q4 2008($0.13)($0.21)ViewN/AView Earnings Details
11/6/2008Q3 2008($0.14)($0.14)ViewN/AView Earnings Details
8/8/2008Q2 2008($0.13)($0.14)ViewN/AView Earnings Details
5/8/2008Q1 2008($0.12)($0.13)ViewN/AView Earnings Details
3/13/2008Q4 2007($0.09)($0.11)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Halozyme Therapeutics (NASDAQ:HALO) Earnings Estimates

2018 EPS Consensus Estimate: ($1.07)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.25)($0.25)($0.25)
Q2 20181($0.26)($0.26)($0.26)
Q3 20181($0.27)($0.27)($0.27)
Q4 20181($0.29)($0.29)($0.29)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Halozyme Therapeutics (NASDAQ:HALO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Halozyme Therapeutics (NASDAQ HALO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 16.80%
Institutional Ownership Percentage: 81.56%
Insider Trades by Quarter for Halozyme Therapeutics (NASDAQ:HALO)
Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics (NASDAQ HALO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/20/2015Laurie StelzerCFOBuy10,000$17.24$172,400.00View SEC Filing  
6/18/2015Kenneth J KelleyDirectorSell20,000$21.00$420,000.00View SEC Filing  
9/16/2014David A RamsayCFOBuy25,000$8.90$222,500.00View SEC Filing  
9/16/2014Helen TorleyCEOBuy50,000$8.92$446,000.00View SEC Filing  
8/19/2014John Stuart PattonDirectorSell75,000$9.96$747,000.00View SEC Filing  
5/15/2014Robert EnglerDirectorSell126,700$7.56$957,852.00233,176View SEC Filing  
9/16/2013John Stuart PattonDirectorSell75,000$9.13$684,750.00155,000View SEC Filing  
8/19/2013H. Michael ShepardVPSell10,000$7.11$71,100.00View SEC Filing  
8/14/2013Kathryn FalbergDirectorBuy100,000$6.82$682,000.00280,000View SEC Filing  
11/29/2012Robert EnglerDirectorBuy15,000$5.57$83,550.00View SEC Filing  
11/14/2012James P ShafferVPBuy20,000$5.22$104,400.00View SEC Filing  
11/13/2012Kathryn E FalbergDirectorBuy50,000$5.21$260,500.00View SEC Filing  
8/27/2012Kenneth J KelleyDirectorBuy20,000$5.70$114,000.00View SEC Filing  
8/13/2012Gregory Ian FrostCEOBuy2,000$5.50$11,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Halozyme Therapeutics (NASDAQ HALO) News Headlines

Source:
DateHeadline
Halozyme Therapeutics (HALO) Price Target Raised to $22.00 at JPMorgan Chase & Co.Halozyme Therapeutics (HALO) Price Target Raised to $22.00 at JPMorgan Chase & Co.
www.americanbankingnews.com - February 21 at 12:45 PM
Halozyme Therapeutics (HALO) Posts Quarterly  Earnings Results, Beats Expectations By $0.27 EPSHalozyme Therapeutics (HALO) Posts Quarterly Earnings Results, Beats Expectations By $0.27 EPS
www.americanbankingnews.com - February 21 at 9:21 AM
After-Hours Stock Movers 02/20: (TTPH) (LPSN) (VRSK) Higher; (RCII) (CATM) (LC) Lower (more...)After-Hours Stock Movers 02/20: (TTPH) (LPSN) (VRSK) Higher; (RCII) (CATM) (LC) Lower (more...)
www.streetinsider.com - February 21 at 8:38 AM
Halozyme Therapeutics (HALO) CEO Helen Torley on Q4 2017 Results - Earnings Call TranscriptHalozyme Therapeutics' (HALO) CEO Helen Torley on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - February 21 at 8:38 AM
$161.76 Million in Sales Expected for Halozyme Therapeutics, Inc. (HALO) This Quarter$161.76 Million in Sales Expected for Halozyme Therapeutics, Inc. (HALO) This Quarter
www.americanbankingnews.com - February 21 at 1:46 AM
Halozyme Therapeutics tops Street 4Q forecastsHalozyme Therapeutics tops Street 4Q forecasts
finance.yahoo.com - February 20 at 5:33 PM
Halozyme Reports Fourth Quarter And Full-Year 2017 ResultsHalozyme Reports Fourth Quarter And Full-Year 2017 Results
finance.yahoo.com - February 20 at 5:33 PM
Halozyme Therapeutics (HALO) Scheduled to Post Earnings on MondayHalozyme Therapeutics (HALO) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - February 19 at 4:30 AM
Halozyme Therapeutics, Inc. (HALO) Given Consensus Rating of "Hold" by BrokeragesHalozyme Therapeutics, Inc. (HALO) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 13 at 5:38 PM
Halozyme Therapeutics Inc (NASDAQ:HALO): Should The Recent Earnings Drop Worry You?Halozyme Therapeutics Inc (NASDAQ:HALO): Should The Recent Earnings Drop Worry You?
finance.yahoo.com - February 9 at 4:13 PM
First Eagle Reduces Halozyme Therapeutics StakeFirst Eagle Reduces Halozyme Therapeutics Stake
finance.yahoo.com - February 6 at 3:53 PM
First Eagle Reduces Halozyme Therapeutics by a ThirdFirst Eagle Reduces Halozyme Therapeutics by a Third
finance.yahoo.com - February 6 at 9:40 AM
Halozyme Therapeutics (HALO) Research Coverage Started at Goldman Sachs GroupHalozyme Therapeutics (HALO) Research Coverage Started at Goldman Sachs Group
www.americanbankingnews.com - January 28 at 5:10 PM
Halozyme Therapeutics (HALO) Stock Rating Lowered by Zacks Investment ResearchHalozyme Therapeutics (HALO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 28 at 11:40 AM
Today’s Research Reports on Stocks to Watch: Cerus Corporation and Halozyme TherapeuticsToday’s Research Reports on Stocks to Watch: Cerus Corporation and Halozyme Therapeutics
finance.yahoo.com - January 25 at 9:45 AM
Deutsche Bank Analysts Give Halozyme Therapeutics (HALO) a $21.00 Price TargetDeutsche Bank Analysts Give Halozyme Therapeutics (HALO) a $21.00 Price Target
www.americanbankingnews.com - January 24 at 10:50 PM
Halozyme Therapeutics: ENHANZE Alone Is Well Worth A Huge Bet On This Underfollowed Biotech - Seeking AlphaHalozyme Therapeutics: ENHANZE Alone Is Well Worth A Huge Bet On This Underfollowed Biotech - Seeking Alpha
seekingalpha.com - January 24 at 8:21 AM
Halozyme To Host Fourth Quarter And Full-Year 2017 Financial Results Conference CallHalozyme To Host Fourth Quarter And Full-Year 2017 Financial Results Conference Call
finance.yahoo.com - January 22 at 9:23 AM
Glancy Prongay & Murray LLP Commences Investigation on Behalf of Halozyme Therapeutics, Inc. Investors (HALO) - Business Wire (press release)Glancy Prongay & Murray LLP Commences Investigation on Behalf of Halozyme Therapeutics, Inc. Investors (HALO) - Business Wire (press release)
www.businesswire.com - January 20 at 7:37 AM
Halozyme Therapeutics, Inc. (HALO) Receives Average Rating of "Hold" from BrokeragesHalozyme Therapeutics, Inc. (HALO) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - January 19 at 7:36 PM
Glancy Prongay & Murray LLP Commences Investigation on Behalf of Halozyme Therapeutics, Inc. Investors (HALO)Glancy Prongay & Murray LLP Commences Investigation on Behalf of Halozyme Therapeutics, Inc. Investors (HALO)
finance.yahoo.com - January 19 at 3:29 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Halozyme Therapeutics, Inc ... - PR Newswire (press release)SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Halozyme Therapeutics, Inc ... - PR Newswire (press release)
www.prnewswire.com - January 18 at 3:26 PM
This News Explains Halozyme Therapeutics Double-Digit Drop Today - Motley FoolThis News Explains Halozyme Therapeutics' Double-Digit Drop Today - Motley Fool
www.fool.com - January 18 at 3:26 PM
Why Halozyme Went Down Yesterday? - Seeking AlphaWhy Halozyme Went Down Yesterday? - Seeking Alpha
seekingalpha.com - January 18 at 3:26 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Halozyme Therapeutics, Inc. - HALOSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Halozyme Therapeutics, Inc. - HALO
finance.yahoo.com - January 17 at 3:25 PM
This News Explains Halozyme Therapeutics' Double-Digit Drop TodayThis News Explains Halozyme Therapeutics' Double-Digit Drop Today
finance.yahoo.com - January 17 at 3:25 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Halozyme Therapeutics, Inc. (HALO)SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Halozyme Therapeutics, Inc. (HALO)
finance.yahoo.com - January 17 at 3:25 PM
This News Explains Halozyme Therapeutics Double-Digit Drop TodayThis News Explains Halozyme Therapeutics' Double-Digit Drop Today
www.fool.com - January 17 at 1:47 PM
$0.60 Earnings Per Share Expected for Halozyme Therapeutics, Inc. (HALO) This Quarter$0.60 Earnings Per Share Expected for Halozyme Therapeutics, Inc. (HALO) This Quarter
www.americanbankingnews.com - January 17 at 1:26 AM
Halozyme Therapeutics Target of Unusually Large Options Trading (HALO)Halozyme Therapeutics Target of Unusually Large Options Trading (HALO)
www.americanbankingnews.com - January 13 at 3:15 AM
Stocks To Watch: Halozyme Therapeutics Sees RS Rating Rise To 92Stocks To Watch: Halozyme Therapeutics Sees RS Rating Rise To 92
finance.yahoo.com - January 11 at 3:25 PM
Halozyme Projects 25 To 30 Percent ENHANZE Royalty Growth In 2018 - PR Newswire (press release)Halozyme Projects 25 To 30 Percent ENHANZE Royalty Growth In 2018 - PR Newswire (press release)
www.prnewswire.com - January 10 at 8:19 AM
Halozyme Projects 25 To 30 Percent ENHANZE Royalty Growth In 2018Halozyme Projects 25 To 30 Percent ENHANZE Royalty Growth In 2018
finance.yahoo.com - January 10 at 8:19 AM
 Brokerages Anticipate Halozyme Therapeutics, Inc. (HALO) Will Announce Quarterly Sales of $160.83 Million Brokerages Anticipate Halozyme Therapeutics, Inc. (HALO) Will Announce Quarterly Sales of $160.83 Million
www.americanbankingnews.com - January 2 at 6:44 PM
Halozyme Therapeutics, Inc. :HALO-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018Halozyme Therapeutics, Inc. :HALO-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018
finance.yahoo.com - January 1 at 3:24 PM
Halozyme Therapeutics To Present At The 36th Annual J.P. Morgan Healthcare ConferenceHalozyme Therapeutics To Present At The 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - December 27 at 9:16 AM
Zacks Investment Research Lowers Halozyme Therapeutics (HALO) to HoldZacks Investment Research Lowers Halozyme Therapeutics (HALO) to Hold
www.americanbankingnews.com - December 25 at 11:40 PM
Halozyme Therapeutics, Inc. (HALO) Receives Consensus Rating of "Hold" from BrokeragesHalozyme Therapeutics, Inc. (HALO) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - December 25 at 5:57 PM
BidaskClub Lowers Halozyme Therapeutics (HALO) to HoldBidaskClub Lowers Halozyme Therapeutics (HALO) to Hold
www.americanbankingnews.com - December 25 at 4:27 PM
FY2017 EPS Estimates for Halozyme Therapeutics, Inc. (HALO) Cut by Jefferies GroupFY2017 EPS Estimates for Halozyme Therapeutics, Inc. (HALO) Cut by Jefferies Group
www.americanbankingnews.com - December 25 at 2:28 AM
Halozyme Therapeutics Sees Unusually Large Options Volume (HALO)Halozyme Therapeutics Sees Unusually Large Options Volume (HALO)
www.americanbankingnews.com - December 24 at 1:20 AM
ETFs with exposure to Halozyme Therapeutics, Inc. : December 19, 2017ETFs with exposure to Halozyme Therapeutics, Inc. : December 19, 2017
finance.yahoo.com - December 19 at 3:24 PM
Halozyme Therapeutics (HALO) Raised to "Buy" at BidaskClubHalozyme Therapeutics (HALO) Raised to "Buy" at BidaskClub
www.americanbankingnews.com - December 17 at 5:20 PM
Why Halozyme Therapeutics (HALO) Could Be Positioned for a Surge - NasdaqWhy Halozyme Therapeutics (HALO) Could Be Positioned for a Surge - Nasdaq
www.nasdaq.com - December 17 at 7:47 AM
$177.14 Million in Sales Expected for Halozyme Therapeutics, Inc. (HALO) This Quarter$177.14 Million in Sales Expected for Halozyme Therapeutics, Inc. (HALO) This Quarter
www.americanbankingnews.com - December 16 at 2:52 PM
Halozyme Therapeutics Reaches Analyst Target PriceHalozyme Therapeutics Reaches Analyst Target Price
www.nasdaq.com - December 14 at 3:24 PM
Zacks: Analysts Expect Halozyme Therapeutics, Inc. (HALO) to Post $0.71 Earnings Per ShareZacks: Analysts Expect Halozyme Therapeutics, Inc. (HALO) to Post $0.71 Earnings Per Share
www.americanbankingnews.com - December 14 at 7:16 AM
Halozyme Therapeutics (HALO) Stock Rating Upgraded by Zacks Investment ResearchHalozyme Therapeutics (HALO) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - December 13 at 1:00 AM
Options Traders Expect Huge Moves in Halozyme Therapeutics (HALO) StockOptions Traders Expect Huge Moves in Halozyme Therapeutics (HALO) Stock
finance.yahoo.com - December 12 at 3:24 PM
Halozyme Therapeutics (HALO) and GW Pharmaceuticals PLC- (GWPH) Head-To-Head ComparisonHalozyme Therapeutics (HALO) and GW Pharmaceuticals PLC- (GWPH) Head-To-Head Comparison
www.americanbankingnews.com - December 12 at 9:26 AM

SEC Filings

Halozyme Therapeutics (NASDAQ:HALO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Halozyme Therapeutics (NASDAQ:HALO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Halozyme Therapeutics (NASDAQ HALO) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.